[18F]-FDG-PET is proposed to be used as a marker of neurodegeneration in the A/T/N framework of Alzheimer’s disease which categorizes AD biomarkers according to the aspects of AD neuropathology that they reflect (A: amyloid accumulation; T: tau accumulation, or N: neurodegeneration) [74]. This evidence concerns the gene MAPT and Alzheimer disease.